Table 1.
Cox regression analysis of CHML expression in 559 MM patients patients in dataset GSE24080.
| 95% CI for HR | ||||
|---|---|---|---|---|
| HR | Lower | Upper | P-value | |
| EFS | ||||
| B2M (>= 3.5 mg/l) | 1.43 | 1.05 | 1.95 | 2.18E-02 |
| ALB (>= 35 g/l) | 0.87 | 0.61 | 1.23 | 4.32E-01 |
| HGB (>= 100 g/l) | 0.78 | 0.58 | 1.05 | 1.05E-01 |
| MRI (>= 3 focal lesions) | 1.47 | 1.13 | 1.93 | 4.85E-03 |
| BMPC (>= 35%) | 1.43 | 1.04 | 1.96 | 2.90E-02 |
| CHML (>=10.55) | 1.86 | 1.43 | 2.42 | 4.34E-06 |
| OS | ||||
| B2M (>= 3.5 mg/l) | 1.67 | 1.15 | 2.44 | 7.49E-03 |
| ALB (>= 35 g/l) | 0.70 | 0.47 | 1.04 | 7.84E-02 |
| HGB (>= 100 g/l) | 0.89 | 0.62 | 1.27 | 5.08E-01 |
| MRI (>= 3 focal lesions) | 1.99 | 1.42 | 2.79 | 7.04E-05 |
| BMPC (>= 35%) | 1.35 | 0.91 | 2.00 | 1.35E-01 |
| CHML (>=10.55) | 2.32 | 1.69 | 3.17 | 1.44E-07 |
CI, confidence interval; HR, hazard ratio. EFS, Event-free survival time (months), the date of definition is from registration to death of any reason, disease progression or recurrence, or checked at the last contact; OS, Overall survival time (months), the date of definition is from registration to death of any reason or checked at the last contact. B2M, Beta-2 microglobulin (mg/l); ALB, Albumin (g/l); HGB, Haemoglobin (g/l); MRI, Number of magnetic resonance imaging (MRI)-defined focal lesions (skull, spine, pelvis); BMPC, Bone marrow biopsy plasma cells (%); CHML, Choroideremia-like.